Literature DB >> 10924445

Heparin should be administered to every patient admitted to the hospital with possible unstable angina.

G S Brewster1, M E Herbert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10924445      PMCID： PMC1071027          DOI： 10.1136/ewjm.173.2.138

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  17 in total

Review 1.  Heparin-induced thrombocytopenia.

Authors:  B H Chong
Journal:  Br J Haematol       Date:  1995-03       Impact factor: 6.998

2.  Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.

Authors:  A Oler; M A Whooley; J Oler; D Grady
Journal:  JAMA       Date:  1996-09-11       Impact factor: 56.272

3.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).

Authors: 
Journal:  Eur Heart J       Date:  1999-11       Impact factor: 29.983

4.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

Authors:  E M Antman; C H McCabe; E P Gurfinkel; A G Turpie; P J Bernink; D Salein; A Bayes De Luna; K Fox; J M Lablanche; D Radley; J Premmereur; E Braunwald
Journal:  Circulation       Date:  1999-10-12       Impact factor: 29.690

5.  Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.

Authors:  J A Cairns; M Gent; J Singer; K J Finnie; G M Froggatt; D A Holder; G Jablonsky; W J Kostuk; L J Melendez; M G Myers
Journal:  N Engl J Med       Date:  1985-11-28       Impact factor: 91.245

6.  Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.

Authors:  E P Gurfinkel; E J Manos; R I Mejaíl; M A Cerdá; E A Duronto; C N García; A M Daroca; B Mautner
Journal:  J Am Coll Cardiol       Date:  1995-08       Impact factor: 24.094

7.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

8.  Optimal therapeutic level of heparin therapy in patients with venous thrombosis.

Authors:  R D Hull; G E Raskob; D Rosenbloom; J Lemaire; G F Pineo; B Baylis; J S Ginsberg; A A Panju; P Brill-Edwards; R Brant
Journal:  Arch Intern Med       Date:  1992-08

9.  Risk stratification in unstable angina. Prospective validation of the Braunwald classification.

Authors:  J E Calvin; L W Klein; B J VandenBerg; P Meyer; J V Condon; R J Snell; L M Ramirez-Morgen; J E Parrillo
Journal:  JAMA       Date:  1995-01-11       Impact factor: 56.272

10.  Prediction of the need for intensive care in patients who come to emergency departments with acute chest pain.

Authors:  L Goldman; E F Cook; P A Johnson; D A Brand; G W Rouan; T H Lee
Journal:  N Engl J Med       Date:  1996-06-06       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.